Thank speak you today. good to a with Lonnel, everyone. pleasure It's all and you, morning,
heart a growing help clinical XXXX, the year-over-year and inhibitors branded grown dynamics, inhibitor market August with for almost failure market XX% specific rapidly continue like around tremendous momentum, heart the utilization differentiated data billion. XX% failure growth patient for $X heart representing with by this XXXX failure has providing updated SGLT which least failure to in the with heart population. opportunity INPEFA, was treatment of starting growing at of a XX% heart Even fuel the that indicated this from of in the last inhibitors treatment entire growing year, So use significant treatment guidelines compelling to by XXXX, SGLT only failure through indication.
SGLT opportunity of for evidence of new has and
will X you launch, formulary slide, next the critical focus namely see the and On access. areas demand generation for INPEFA
that the by on fronts. momentum both encouraged these of are building are we We
heart at look trial we with the focused on the generation, awareness in demand have majority As in INPEFA patients States. treat United teams who failure of our driving of writers high-volume been
As cross-functional -- a key the grown area for focus remain for result moving has will of of QX throughout these unique teams strategic prescribers INPEFA a our number efforts, of and the unique forward.
data full as as expected build. in INPEFA. an that our It's first to which formula INPEFA our seeing conditions improving launch, meaningful by the noting demand data, we close outpaced as submitted quarter seen paid is we increases has of continues access reflecting filled acceleration for commercial out prescriptions, are we have claims worth Importantly, prescription evidenced in that access
engaged and been targeted plans national plans access, layers the and both QX. successfully formulary focused with multiple on In with engagements of terms throughout has payer all regional discussions with has team of
release press morning, in to Medicare this continue we executed throughout and our expect access formulary in in channels, QX. announced we were commercial and As contracts key both QX access
SOLOIST patient more for also population the share of also remain and delivery data integrated networks, a IDNs, valuable the will about given rehospitalization or focus today uniqueness We strategic information INPEFA. which
launch to Turning quarterly additional metrics.
as to initial here a accelerate shipments June, throughout data. up demand third wholesalers continued used prescriptions received ex-factory see a wholesalers, in a orders unique we of You and continued quarter. the see data through on of have that to the quarter view and trend shipments prescribers summary the Ex-factory will
mentioned for prescriber the expanded which of As high INPEFA, which the we unique health growing majority quarter, are base from nearly has high-priority, professionals key previously, the hyper-focused XXX to prescriber targets. on care through are
a as filled achieves the INPEFA with growing will lead With that demand been clinical have coverage. to nearly encouraged filled this large outpacing to we X:X. data formulary clinical We by contracted of believe data access see build greater demand prescription continuing payers, our ratio national prescriptions to additional growing
weeks are the IQVIA third-party week see the also alongside prescriptions that you throughout on filled XXXX acceleration and the grow invisible that will which with to As slide, noting are worth continue this last It's directly those next reflects our Symphony, few week in pharmacy, QX specialty number through going prescriptions reported agencies. quarter. of over to through being an not
on belief our demonstrating and slide, demand claims has with field the prescriptions mentioned clinical prior the through of QX, by line filled customer INPEFA. of teams outpaced value in offered number the clearly impact nearly As top the X,XXX submitted
progress Turning coverage. to our on payer
with additions Medicare The contracting added plan We coverage see and are given and QX for major of We pleased significant process Medicare national plans additional commercial do to been are outside into additions across to INPEFA the through next that particularly expect throughout formularies. to coverage normal have payers. early both QX grow these year. be
Integrated IDNs. a to our Turning launch Delivery Networks component key of remain strategy.
product and of all on heart execution contracting able and organization. has GPO for negotiations into their purchasing commercial targeted Given in Once primary systems launch been was additions, lives the with later completed, QX XX% failure expect focus quarter which reviews, INPEFA already team of progress our X coverage. an The been INPEFA contract summary, in during fully represent begin block the and clinically launch entire executed. to the institutions. The with across both contracts group formulary building has major IDN the meaningful typical this X IDN made the will which foundations organizations, strategy important for year evaluate we of executed of new-to-market on the around is XXXX.
In QX have for financially to formulary initiated be our
We an they treatment overview recent since are clinical SGLTX/X further wherever of launch failure. community releases the the and positive accelerating call give inhibitor most given momentum heart heart helping the build to positive for.
I begun for even more laser-focused the the the to patients may over be the of with medical only now indicated to as have for INPEFA. we by INPEFA Craig reception to pleased turn The data and scientific will on worsening by failure cared team remains
